SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2023
Commission File Number: 001-40858
XORTX Therapeutics Inc.
3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|XORTX THERAPEUTICS INC.|
|Date:||March 31, 2023||By:||/s/ Allen Davidoff|
Chief Executive Officer
|99.1||Consolidated Financial Statements for the year ended December 31, 2022, 2021 and 2020|
|99.2||Management Discussion and Analysis for the year ended December 31, 2022|
|99.3||Annual Information Form for the year ended December 31, 2022|